Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Joan Mannick"'
Autor:
Yves Rolland, Felipe Sierra, Luigi Ferrucci, Nir Barzilai, Rafael De Cabo, Joan Mannick, Anthony Oliva, William Evans, Davide Angioni, Philipe De Souto Barreto, Jeremy Raffin, Bruno Vellas, James L. Kirkland, the G.C.T-TF group
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to
Externí odkaz:
https://doaj.org/article/eb01587548254b758eb55498e901135e
Autor:
Mercy PrabhuDas, Rebecca Fuldner, Donna Farber, George A. Kuchel, Joan Mannick, Janko Nikolich-Zugich, Ranjan Sen, Joanne Turner
Publikováno v:
Nat Aging
On 16 and 17 March 2021, the National Institute of Allergy and Infectious Diseases and the National Institute of Aging convened a virtual workshop to discuss developments in SARS-CoV-2 research pertaining to immune responses in older adults, COVID-19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fe0f884e2bdf45ff239e7671ff71f71
https://europepmc.org/articles/PMC9997058/
https://europepmc.org/articles/PMC9997058/
Autor:
Reginald Valdez, Lin Fan, Yanqun Wang, Jiang Zhu, Sharon X. Wang, David J. Glass, Tea Shavlakadze, Joan Mannick, Weihua Zhou, Angelika Meyer, Oleg Iartchouk, Marc A. Egerman, Lloyd B. Klickstein, Bret Morin
Publikováno v:
The Journals of Gerontology: Series A. 73:845-852
Rapalogs, inhibitors of mTORC1 (mammalian target of rapamycin complex 1), increase life span and delay age-related phenotypes in many species. However, the molecular mechanisms have not been fully elucidated. We determined gene expression changes com
Publikováno v:
Open Forum Infectious Diseases
Background Respiratory tract infections (RTIs) are a leading cause of hospitalization and death in people age ≥65 years. RTIs are caused by multiple viruses, most of which lack effective treatments. An immunotherapy that enhances pan-antiviral inna
Publikováno v:
B15. IMMUNOTHERAPY FOR LUNG DISEASE.
Autor:
Joan Mannick
Publikováno v:
Innovation in Aging
Autor:
Joan Mannick
Publikováno v:
Innovation in Aging
Inhibition of TORC1 has extended lifespan in multiple preclinical species. Thus drugs inhibiting TORC1 may have therapeutic benefit for aging-related conditions in humans. An aging-related condition that improves with TORC1 inhibition in old mice is
Autor:
Melody Morris, Weihua Zhou, Mollie Watkins, Martin Beibel, Hans-Ulrich P. Hockey, Kenneth Kulmatycki, Joan Mannick, Guglielmo Roma, Tea Shavlakadze, Dean Quinn, Lloyd B. Klickstein, David J. Glass
mTOR inhibition extends lifespan and ameliorates aging-related pathologies including declining immune function in model organisms. The objective of this Phase 2a clinical trial was to determine if low dose mTOR inhibitor therapy enhanced immune funct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c4ab1cbb80a51d1cf90e4776949a45f
https://doi.org/10.1101/230813
https://doi.org/10.1101/230813
Publikováno v:
Current Pharmaceutical Biotechnology. 12:2176-2189
The role of TGF-β in tumor development and progression is complex. Genetic mutations that disrupt the antiproliferative signaling effects of TGF-β play a key role in the process of malignant transformation for many types of tumors. Paradoxically, t
Autor:
Simon Carson, Michael A. Lonetto, John S. Kovarik, Holden T. Maecker, Jens Praestgaard, Maria Lattanzi, Nicholas Valiante, Baisong Huang, Joan Mannick, Lloyd B. Klickstein, David J. Glass, Giuseppe Del Giudice
Publikováno v:
Science Translational Medicine. 6
Inhibition of the mammalian target of rapamycin (mTOR) pathway extends life span in all species studied to date, and in mice delays the onset of age-related diseases and comorbidities. However, it is unknown if mTOR inhibition affects aging or its co